Toll Brothers
TOL
Meritage Homes
MTH
Taylor Morrison Home
TMHC
D.R. Horton
DHI
KB Home
KBH
US Stock MarketDetailed Quotes
TNDM Tandem Diabetes Care
- 37.490
- +0.440+1.19%
Close Jan 8 16:00 ET
- 36.554
- -0.936-2.50%
Pre 08:34 ET
2.46BMarket Cap-19.32P/E (TTM)
37.800High35.030Low936.19KVolume36.750Open37.050Pre Close34.62MTurnover1.44%Turnover RatioLossP/E (Static)65.68MShares53.69052wk High10.36P/B2.44BFloat Cap21.85052wk Low--Dividend TTM65.12MShs Float302.500Historical High--Div YieldTTM7.48%Amplitude2.140Historical Low36.980Avg Price1Lot Size
Tandem Diabetes Care News
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $44
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $65
Bernstein Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $42
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Tandem Diabetes Care Analyst Ratings
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $50
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $40
Tandem Diabetes Care Poised for Growth: Expansion Into Type 2 Diabetes and Strategic Integration Drive Buy Rating
Tandem Diabetes Care Raised to Overweight From Equal-Weight by Morgan Stanley
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Maintains Target Price $45
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $40 to $75
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Tandem Diabetes Care Analyst Ratings
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $37 to $65
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.